SCHEDULE: Baker Bros. Shifts KALA BIO Stake to Passive 9.99%

Baker Bros. Advisors and affiliates have reclassified their KALA BIO, Inc. stake to a passive 9.99% ownership, relinquishing board nomination rights.

Summary

• Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker (collectively, the "Reporting Persons") have filed a Schedule 13G for KALA BIO, Inc.
• The Reporting Persons beneficially own an aggregate of 744,759 shares of KALA BIO, Inc. Common Stock, representing 9.99% of the outstanding class.
• This ownership includes 434,200 shares of Common Stock issuable upon the conversion of 4,342 Series E non-voting convertible non-redeemable preferred stock.
• The percentage of beneficial ownership is calculated based on 7,021,040 shares of Common Stock outstanding as of August 7, 2025, plus the 434,200 convertible Series E Preferred shares.
• The filing indicates a shift from a Schedule 13D to a Schedule 13G, signifying that the Reporting Persons now hold securities in the ordinary course of business without the purpose or effect of changing or influencing the control of KALA BIO, Inc.
• This change was triggered by sales disclosed in a previous 13D filing on October 2, 2025, which resulted in the Baker Bros. Funds (667 L.P. and Baker Brothers Life Sciences, L.P.) no longer having the right to nominate individuals for election to KALA BIO's Board of Directors.
• The Convertible Preferred Stock (Series E, F, G, H) is subject to a beneficial ownership limitation, preventing conversion if it would result in ownership exceeding 9.99% of outstanding Common Stock, though this limit can be increased to 19.99% with 61 days' notice to the Issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. While Baker Bros. maintains a significant stake, the relinquishment of board nomination rights due to prior sales suggests a reduction in active engagement and influence, which can be viewed unfavorably by the market regarding a major investor's confidence.

Positives

• A significant institutional investor, Baker Bros. Advisors, maintains a substantial 9.99% stake in KALA BIO, Inc., indicating continued investment interest.
• The shift to a passive Schedule 13G filing may reduce perceived activist pressure on KALA BIO's management and board.

Negatives

• Baker Bros. Advisors and its affiliated funds have relinquished their right to nominate individuals for election to KALA BIO's Board of Directors, potentially reducing direct oversight from a major investor.
• The change in reporting status was a result of sales by the Reporting Persons, which could be interpreted as a reduction in their active engagement or confidence in the company's strategic direction.

Risks

• The beneficial ownership limitation on the Convertible Preferred Stock (Series E, F, G, H) restricts the immediate conversion of these shares if it would exceed 9.99% of the outstanding Common Stock, potentially limiting liquidity or influence for the holders.
• The number of shares of Common Stock issuable upon conversion of the Convertible Preferred may change based on fluctuations in the outstanding shares of Common Stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance from KALA BIO, Inc. or the Reporting Persons regarding the company's future performance or strategic direction.

Industry Context

This filing reflects a common occurrence in the biotechnology sector where institutional investors, after an initial period of active engagement (often indicated by a Schedule 13D filing), may transition to a more passive investment stance (Schedule 13G) as their strategic objectives or the company's development evolve. The maintenance of a significant stake, even passively, can still signal underlying value perception.

Corporate Governance

Stakeholder Impact

• Shareholders: May experience reduced activist pressure from a major investor but also less direct oversight and advocacy from a significant stakeholder on the board.
• Management: May have greater autonomy without the direct board nomination rights of Baker Bros. Funds, but could also lose a source of strategic guidance or challenge.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Baker Bros. Advisors, has shifted its KALA BIO stake to a passive position, relinquishing board nomination rights due to prior sales. While the 9.99% ownership remains substantial, the reduction in active influence and the underlying sales that triggered this change could be perceived as a negative signal. However, the filing itself does not provide new financial performance data or strategic updates from KALA BIO. Therefore, a 'hold' recommendation is appropriate, pending further information on KALA BIO's operational performance and strategic direction, as this filing primarily reflects a change in investor status rather than company fundamentals.

Keywords

KALA BIO, Baker Bros. Advisors, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Institutional Investor, Biotechnology, SEC Filing, Ownership Disclosure